[{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Denileukin Diftitox","moa":"Elongation factor 2 | Interleukin-2 receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"15","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CANADA","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Base Egg Protein","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Consomm\u00e9 Soup","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Undisclosed"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Glytactin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mixed Essential Amino Acids","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Sodium Glutamate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Undisclosed"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Ajinomoto Company","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Daniel Moore","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Amino acid metabolism","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Daniel Moore","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Daniel Moore"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Elizabeth Anne Thiele","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Amino Acid","year":"2024","type":"Inapplicable","leadProduct":"L-Leucine","moa":"Leucine--tRNA ligase, mitochondrial; tRNA wybutosine-synthesizing protein 4; Leucine carboxyl methyltransferase 1; Leucine--tRNA ligase, cytoplasmic; Branched-chain-amino-acid aminotransferase, mitochondrial; Branched-chain-amino-acid aminotransferase, cytosolic","graph1":"Neurology","graph2":"Phase I","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ajinomoto Company \/ Elizabeth Anne Thiele","highestDevelopmentStatusID":"6","companyTruncated":"Ajinomoto Company \/ Elizabeth Anne Thiele"}]

Find Clinical Drug Pipeline Developments & Deals by Ajinomoto Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Leucine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistant Epilepsy.

                          Product Name : Undisclosed

                          Product Type : Amino Acid

                          Upfront Cash : Inapplicable

                          April 26, 2024

                          Lead Product(s) : L-Leucine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Elizabeth Anne Thiele

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Lead Product(s) : Glytactin

                          Therapeutic Area : Genetic Disease

                          Study Phase : Undisclosed

                          Sponsor : Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Glytactin is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Phenylketonurias.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 27, 2024

                          Lead Product(s) : Glytactin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.

                          Product Name : Lymphir

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          July 29, 2023

                          Lead Product(s) : Denileukin Diftitox

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Citius Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          October 24, 2017

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Amino Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 22, 2017

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Sponsor : Daniel Moore

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Base Egg Protein is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Diseases.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 22, 2016

                          Lead Product(s) : Base Egg Protein

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Amino Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 08, 2016

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Amino Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 15, 2016

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : This drug candidate is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          June 15, 2016

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Amino Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Diseases.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 10, 2015

                          Lead Product(s) : Amino Acids Mixture

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : University of Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank